Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:55:14 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MRKR - MARKER THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRKR - Q0.14.01·4.290.14.1154-0.2446-5.612.350504.29  4.41  4.11549.6799  0.7614:34:21Apr 0815 min RT 2¢

Recent Trades - Last 10 of 50
Time ETExPriceChangeVolume
14:34:21Q4.02-0.271
14:34:21Q4.02-0.271
14:34:17Q4.02-0.271
14:34:17Q4.02-0.2710
14:32:37Q4.02-0.2724
14:27:01Q4.02-0.2756
14:22:17Q4.01-0.2810
14:03:18Q4.02-0.275
14:03:18Q4.02-0.277
14:03:18Q4.11-0.1830

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 07:01U:MRKRNews ReleasePrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
2024-03-26 12:44U:MRKRSEDAR Annual ReportSEDAR MD & A
2024-03-25 17:45U:MRKRNews ReleaseMarker Therapeutics Reports Year-End 2023 Corporate and Financial Results
2024-03-22 12:31U:MRKRNews ReleaseMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
2024-01-22 07:30U:MRKRNews ReleaseMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for ¢ € œNeldaleucel ¢ €  as Nonproprietary Name for MT-601
2024-01-08 08:25U:MRKRNews ReleaseMarker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
2023-12-21 11:00U:MRKRNews ReleaseMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During ¢ € œJ.P. Morgan Week 2024 ¢ € 
2023-12-11 07:00U:MRKRNews ReleaseMarker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
2023-11-09 20:40U:MRKRSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 20:35U:MRKRSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-09 17:00U:MRKRNews ReleaseMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-09-11 07:00U:MRKRNews ReleaseMarker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
2023-08-30 08:01U:MRKRNews ReleaseMarker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 09:04U:MRKRNews ReleaseMarker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
2023-08-14 18:01U:MRKRSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-14 16:30U:MRKRNews ReleaseMarker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-08-07 07:00U:MRKRNews ReleaseMarker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
2023-07-26 07:00U:MRKRNews ReleaseMarker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
2023-07-10 07:00U:MRKRNews ReleaseEuropean Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
2023-06-26 07:00U:MRKRNews ReleaseMarker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration